chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I have had blurred vision since I got home from getting my first shot; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 07Apr2021 at 09:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as patient was diabetic and had asthma. The patient had previously taken Barbiturates and experienced drug allergy. The patient previously took ciprofloxacin (MANUFACTURER UNKNOWN), chlorhexidine (MANUFACTURER UNKNOWN), styrax benzoin tincture (BENZOIN TINCTURE), theophylline(MANUFACTURER UNKNOWN), montelukast (MANUFACTURER UNKNOWN); all on unknown date for unknown indication and experienced drug allergy. The patient had received other prescribed medications (unspecified) within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient has had blurred vision from 07Apr2021 at 10:30, since she got home from getting her first shot on 07Apr2021 at 09:45. No therapeutic measures were taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event had blurred vision since she got home from getting her first shot was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
approx 2yrs p/ vax pt devel chickenpox-like rash w/approx 20 itchy, red papules. treated w/acyclovir
Patient received J&J COVID vaccine on 5/13 at site. Admitted 5/14 with fever, rigors, dyspnea.
Information has been received from a medical assistant referring to an unknown number of patients of unknown age and gender. The patients' pertinent medical history and drug reactions/allergies were not reported. On unknown dates, the patients were inadvertently vaccinated with ROTATEQ (lot # K007247 with expiration date 17-MAR-2016, orally; strength, dose and dose number were not reported), which had been improperly stored. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.
feeling bloated "like really super bad"; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISTENSION (feeling bloated "like really super bad") in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL DISTENSION (feeling bloated "like really super bad"). At the time of the report, ABDOMINAL DISTENSION (feeling bloated "like really super bad") outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Vaccine administered 13:50, adverse event started 14:05. Patient had flushing/sweating, tachycardia. BP 114/68 -- > 119/68, HR 70 -- > 70, RR = 16 -- > 16, Temp 98F -- > 98F, O2 sat = 100%. At 14:52, patient denied lightheadedness, patient stable, released from vaccination site.
Sore arm at site where vaccination was given, Right arm; limited mobility; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46-year-old patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), administered in arm right (Batch/Lot number: unknown) as dose number unknown, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "Sore arm at site where vaccination was given, Right arm"; MOBILITY DECREASED (non-serious), outcome "unknown", described as "limited mobility". Therapeutic measures were not taken as a result of vaccination site pain, mobility decreased.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a healthcare worker referring to a 12 year old patient of unknown gender. Information regarding concurrent conditions and medical history was not provided. On 13-MAY-2015 the patient was inadvertently vaccinated with a 1 ml dose of VAQTA, as their second dose in the series, intramuscularly (lot # and application site were not reported). Concomitant therapy was not reported. No adverse effect reported. Additional information has been requested.
Mild shortness of breath chest tightening sore arm sore throat fever bodyaches chills tingling in left arm where vaccine was given in the fingers stomach upset diarrhea
extreme vomiting for 4 hours, severe abdominal pain and nausea for 18 hours
Caller said that she had the symptoms and got covid; Caller said that she had the symptoms and got covid; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A 67-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "hepatitis B" (unspecified if ongoing), notes: if the product will affect her liver as she had hepatitis B when she was 19 years old. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "Caller said that she had the symptoms and got covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown Results. Clinical course: Caller, 67 years of age wanted to know before starting to take her Paxlovid pills if the product will affect her liver as she had hepatitis B when she was 19 years old. Caller was fully vaccinated with the two shots and one booster of Pfizer. Resolution: Caller said that they had power outage right now and she was calling from her mobile phone. Caller said that will contact again and caller hung up. Medical inquiry was not forwarded to Medical Information.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report was received from a consumer, who posted an article, via a company representative, which refers to a 16 year old female patient. The patients' medical history and concurrent condition were not reported. On an unknown date the patient was vaccinated with GARDASIL (Lot number, expiration date, concentration, route of administration, dose and frequency were not reported). Information regarding concomitant medication was not provided. It was reported that on an unknown date, the patient experienced an "apparently damage to her ovaries after being administered GARDASIL" (ovarian disorder). It was also reported "about how GARDASIL is "deadly" and is supposedly causing damage to women's reproductive systems" (reproductive tract disorder). At the time of the report, the outcome of the adverse events was unknown. The causality between the adverse events and GARDASIL was not reported. Additional information is not expected.
Case number PHEH2014US003620, is an initial spontaneous report from a pharmacist received on 21 Feb 2014 and a follow up report from the pharmacist received on 18 Mar 2014. This report refers to a 14-year-old male patient. The patient's medical history and concomitant medications were not reported. This patient under the age of 18 years was vaccinated with 0.5 ml of FLUCELVAX (batch number: 010021A, expiry date: Jun 2014) intramuscularly in the right arm on 08 Dec 2013. No adverse event was reported following the medication error. No further information was provided. Follow up report from the pharmacist received on 18 mar 2014: The vaccination site was updated. Following an internal review on 18 Aug 2014, a significant correction was done for the information received on 18 Mar 2014: The BPI labeling of the event "Inappropriate age at vaccine administration" changed from listed to unlisted and added second indication as "drug used in unapproved population".
tested positive for Covid, June 1, 2020,  ASYMPTOMATIC Received the vaccine, was extremely fatigued, went to  bed and was on nebulizer for about a week, wheezing terribly, shortness of breath, went into cardiac arrest and passed away
serious headache; nausea; chills; was in bed, mostly sleeping, for 21 hours; This is a spontaneous report from a non-contactable consumer (Patient). A 66-years-old (Age group: Elderly 65+ Years) female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EP7533, Expiration date was not reported), via an unspecified route of administration, in Left Arm on 27Mar2021 10:30 (at the age of 66-years-old) as dose 2, single for covid-19 immunisation. Patient received vaccine at Clinic The patient medical history included sinusitis from an unknown date and unknown if ongoing. The patient concomitant medications included oxybutynin (OXYBUTYNIN); fluticasone (FLUTICASONE); estrogens conjugated (PREMARIN). The patient had no known allergies. The patient previously received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number EN6199, Expiration date was not reported) via an unspecified route of administration, in Left Arm on 06Mar2021 11:30 for covid-19 immunization suffered from headache. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 10:30, the patient experienced serious headache, nausea, chills, was in bed, mostly sleeping, for 21 hours. Patient received treatment of one Vicadin and then 2 tylenol every 5 hours. The patient had recovered from the events on an unspecified date in 2021,
per mom: pt devel T104, severe back pain taken to ER sed rate elevated;triple level of liver enzyme ?abscess on spine;saw MD 4-5 times;pt fine now was hosp for 1wk;
swollen lymph nodes, fatigue headaches Narrative: Employee experienced headache and fatigue. Two days post vaccine the lymph nodes in her arm pit were slightly swollen for two days and then the lymph nodes in her neck were swollen for 5 days. Resolved without medical interventions. Did have employee health look at her.
After receiving first dose of Moderna Covid vaccine, the next morning started having rapid heartbeat, nausea, headache, whole arm soreness, chills. Now 4 days later, still have rapid heartbeat, chills, and mild diarrhea
Pt was given 2 shots on 4/15/10. One was varicella and one was HPV. Immediately after vaccination the pt got lightheaded so we sat her on the floor with head down and feet up until she felt better. She returned back to class that day. The next day (4/16/10) as she was in the lunch line at school her stomach began to hurt and she got dizzy. She went to tell her line teacher. As she got to her and began to tell her she wasn't feeling good she went down and the teacher caught her. She doesn't remember after that. She passed out and peed her pants. Her grandmother and mother were called in and she was taken to the Dr. where lab work was ordered. The found that she was anemic. All lab results will be with VAERS form. Description of incident per RN  administrator of vaccine and per pt mother per phone call.
This spontaneous report was received from a physician via a company representative and refers to a patient of unknown age and gender. On an unknown date, the patient was vaccinated with ZOSTAVAX (dose, frequency, route of administration, lot# and expiration date were not reported) for prophylaxis. On an unknown date, the patient experienced herpes zoster. The outcome of herpes zoster was unknown. The relatedness between the event and ZOSTAVAX was not reported.
Patient received the vaccine and went to sit in the observation area.  About 2 minutes later, she became pale, dizzy, sweaty, and claimed she might have diarrhea.  She was given cold water, a cold compress, helped to the bathroom.  She declined having us call 911.  We took her blood pressure.  We moved her to the vaccination area where she sat with a fan on her.  After about 40 minutes, she stated she was just tired and achy, but she wasn't dizzy any more and she wanted her son to drive her home.
Initial and follow-up information has been received from a physician and a licensed practical nurse concerning a 64 year old male with no known drug allergies, hyperlipidemia, gout, gastrooesophageal reflux, nephrolithiasis, Borrelia burgdorferi infection, and "positive" immunoglobulin G and immunoglobulin M in 2000 who on 04-APR-2007 was vaccinated SC in the left arm with 0.5 mL dose of pneumococcal 23v polysaccharide vaccine (lot #655668/1004P). On 05-APR-2007, at approximately 10:00, the patient developed cellulitis. It was reported that the patient developed erythema and swelling of the distal left arm and forearm. The patient was treated with diphenhydramine HCL and famotidine (MSD). On 10-APR-2007, the patient was seen in the office. At the time, the patient's swelling persisted. On 27-APR-2007, the patient's creatine phosphokinase was noted to be 331. On 05-JUN-2007, the patient's CPK was decreased to 158. On an unspecified date, the patient recovered. A lot check was requested for this vaccine due to the patient's adverse reaction. A standard lot check investigation was performed. All in-process quality checks for the lot number in question were satisfactory. The lot met the requirements of the Center for Biologics Evaluation and Research and was released. It was also reported that three other patients developed cellulitis after vaccination with pneumococcal 23v polysaccharide vaccine (lot #655668/1004F) (WAES #0704USA01549). No additional information is expected.
soreness at the injection site; This is a spontaneous report from a contactable consumer (patient is reporter's mother). A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at SINGLE DOSE for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced soreness at the injection site on an unspecified date with outcome of unknown. The reporter learned the evening of Jan21.  Information on the Lot/batch number has been requested.
C/O blurry vision and HA onset 3 hours after COVID-19 recombinant booster and flu IZ at SPLG 10/13; has to strain to see letters, they appear thick and wide on top and skinny on the bottom; eyes were feeling very strained, no red eye or pain w/EOMs but she couldn't drive starting AM after IZs due to strained vision. Mild HA secondary to eye strain. Blood sugar WNL <140. Endorsed she felt a bit weird too, not dizzy or lightheaded, no CP, palpitations, but her body and stomach 'felt weird.' Denies n/v. Appetite normal. No fever/chills/skin rash/body aches. Called PRIVATE 10/16 after hours then called back 10/17 spoke w/RN reports she told RN her sx and onset s/p IZs but per RN note in chart pt stated sx onset 10/12 - pt was convinced this was an eye problem and she made an appt 10/21 w/ophtho; RN recommended call same day for cancellation. Since then, sx have significantly improved and seem to be resolving. Has to strain a bit still but no vision loss, flashers/floaters, and letters/numbers look more normal. HA and 'weird' sensation also resolving. No new sx. She is amenable to FU with ophtho on 10/21 or ER if sx recurrent/worsening.  Pt reported Blurry vision and L side of Head pain. Pt reported vertical double vision at ER on 10/21
Redness, bruising, rash and skin dryness and burning sensation on both full arms and lesser so on legs and lower back recurring since vaccination
The child started with what initially appeared to be a diaper rash but quickly turned to welts and moved/spread all over her body and face throughout the day and the next several days. We took her to urgent care. They did not administer any medications or treatment. We gave her children's Benadryl at home, which helped reduce the welts swelling, but did not completely make them go away.
This spontaneous report as received from a healthcare student refers to a unspecified number of patients of unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date the patients were vaccinated with a improperly stored GARDASIL  lot # J005679, expiration date 37-NOV-2015. The vaccine was exposed to -2C for 6 days. No adverse effects were reported. Additional information has been requested.
A few hours after receiving the shot I was experiencing lightening bolts in my right eye, then it felt like bugs were flying in the right eye, now there are two black floaters that look like spiders and my eye feels tired.  I've used tear drops, and will contact my ophthalmologist for an appointment.  After a while it gives me a headache.  The shot was given on my left arm, but the eye issues are just on the right side, the right eye.
Injection site swelling with no pain two weeks after vaccine. The day after the injection, I had injection site swelling for about three days then it went away.
pt exp uncontrollable crying from 6PM until 10PM; large red swollen area lt thigh;
I have a rash where the injection shot was given in my left arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (I have a rash where the injection shot was given in my left arm) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (I have a rash where the injection shot was given in my left arm). At the time of the report, VACCINATION SITE RASH (I have a rash where the injection shot was given in my left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was provided. No treatment medication information was provided.
Muscle aches; Some joint pain; Headache; Nausea; This spontaneous case was reported by a patient and describes the occurrence of MYALGIA (Muscle aches), ARTHRALGIA (Some joint pain), HEADACHE (Headache) and NAUSEA (Nausea) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 098F21A, 026B21A and 014M20A) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis (10 years ago, arthritis in knees and hands.), Fibromyalgia (99 percent gone due to being on a gluten free diet.) since 1995, Rheumatic fever (Rheumatic fever as a child), Gluten intolerance (Gluten intolerant), Allergy to antibiotic (Cipro), Sulfonamide allergy (Sulfa), Allergy to antibiotic (Erithromycin), Drug allergy (Steroid), Drug allergy (Motrin), Drug allergy (Advil), Drug allergy (Muscle relaxers) and Drug allergy (Soma).   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 01-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. In 2021, the patient experienced MYALGIA (Muscle aches), ARTHRALGIA (Some joint pain), HEADACHE (Headache) and NAUSEA (Nausea). At the time of the report, MYALGIA (Muscle aches), ARTHRALGIA (Some joint pain), HEADACHE (Headache) and NAUSEA (Nausea) outcome was unknown.            No concomitant medication details was reported.  The patient had reported after the first three doses, patient experienced some joint pain, muscle aches, headache, and nausea. Patient reported that it was not anything bad and patient could push through with those symptoms for a couple of days.  No treatment medication details was reported.   This case was linked to MOD-2022-619530, MOD-2021-034109, MOD-2021-072834 (Patient Link).
Aches and pains fatigue for about 36 hours, took aspirin and rest. Left axillary lymph node swelling size of palm of hand, hard, sore and sensitive, treated with rest, warm, packs, gentle massage (patient is massage therapist) Tongue felt acutely sensitive, as if taste buds had been burned.
Redness, swelling, heat, and patient says it feels like a rock at the injection site. Patients is taking tylenol and using a cold pack. We suggusted on 1/31/18 that the patient go to the doctor if no improvement.
Pt also notes redness/ swelling of left arm after application of PSV 20 vaccine during last visit. States swelling improved, however, redness turned into a bruise. Pt notes improvement in size of bruise over the past couple of days. Mildly tender
Approximately 2 minutes after receiving 3rd HPV immunization, client fainted.  Client was unconscious approximately 10 seconds, for 3-5 of those seconds, client noted to have posturing like movements.  Client's hands were curving into fists at her chest, pointing toes down and head bobbing up and down.  After only 3-5 seconds of that type of movement, client regained consciousness suddenly and was alert.  When asked if she was okay, she smiled and stated "I'm okay".  Whole episode lasted approximately 10 seconds.
SUBCONJUNCTIVAL HEMORRHAGE; ALLERGIC REACTION; TINGLING SENSATION BACK TO LEFT KNEE; This spontaneous report received from a patient concerned a 59 year old female with unknown race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin was not reported, batch number: 1822809, and expiry: 07-MAR-2022) dose was not reported, 1 total administered at left arm on 24-SEP-2021 for prophylactic vaccination. No concomitant medications were reported.  On 24-SEP-2021, the patient experienced subconjunctival hemorrhage, allergic reaction, tingling sensation back to left knee. The patient had no immediate reaction following injection. The patient had developed once a red spot to the eye cornea and it was described as a subconjunctival hemorrhage. The patient denied any respiratory distress or immediate emergency and was aware about clotting issues with hemorrhage of eye. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the subconjunctival hemorrhage, allergic reaction and tingling sensation back to left knee was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20210949991-covid-19 vaccine ad26.cov2.s -Subconjunctival hemorrhage. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
When she was 4, patient was given the wrong vaccination. She was given Adult Hep A, instead of childrens. The error was not reported to us until recently. Patient was in the triage getting treated for 8 hours with a WBC of 29,000+ temp 104.7.